Rituximab as a therapeutic consideration for refractory eosinophilic fasciitis

Int J Dermatol. 2018 May;57(5):614-615. doi: 10.1111/ijd.13940. Epub 2018 Feb 15.

Authors

Amanda F Nahhas¹, Mohsin Alam², Henry W Lim¹

Affiliations

¹ Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.
² Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA.

PMID: 29446454
DOI: 10.1111/ijd.13940

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Administration, Oral
Adrenal Cortex Hormones / administration & dosage
Aged
Arm
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Eosinophilia / diagnostic imaging*
Eosinophilia / drug therapy*
Fasciitis / diagnostic imaging*
Fasciitis / drug therapy*
Follow-Up Studies
Humans
Infusions, Intravenous
Magnetic Resonance Imaging / methods
Male
Methotrexate / administration & dosage
Recurrence
Rituximab / administration & dosage*
Severity of Illness Index
Treatment Outcome

Substances

Adrenal Cortex Hormones
Rituximab
Methotrexate

Supplementary concepts

Eosinophilic Fasciitis